Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Friday 12 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Market Access

US and UK flags in the wind

The UK-US drug pricing deal: A welcome step, but not the fin...

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

R&D

Cells under microscope

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

Patients

pharmaphorum podcast Episode 228, Ruth Chambers, Raparu Consult CIC

The NHS, system burden, and a transformation prescription, w...

Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.

Digital

AI screening of lungs in human body digital display

Garbage in, garbage out: The hidden data crisis in pharma

This hidden data crisis is the fundamental barrier to scaling AI in the life sciences sector.

Oncology

Interview at ESMO 2025 with Dr Ebrahim Delpassand

ESMO25: On radiopharmaceutical possibilities in oncology, wi...

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.

Market Access

HCP holding a vial with organ option holograms

Indication-specific pricing in England: Business as usual?

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.

Digital

Future-Proofing Health Systems: Insights from Frontiers Health 2025

Future-Proofing Health Systems: Insights from Frontiers Heal...

At Frontiers Health 2025, we caught up with Moredreck Chibi (World Health Organization) and Chrys Herrera (Merck KGaA).

Load more results

Sales & Marketing

Sales & Marketing

HCP and patient looking positive

Sponsored

Bridging science and strategy: Medical Affairs at the heart ...

In this sponsored podcast, Cheryl Lubbert and Carolyn Whiting of Reverba discuss a new approach to pharma marketing, omnichannel, and medical affairs.

Sales & Marketing

12 questions with Jim Sage

Sponsored

12 Questions with Jim Sage

Jim Sage is a seasoned global pharmaceutical executive with extensive marketing, commercial, and leadership experience across major therapeutic areas.

Digital

Digital

AI screening of lungs in human body digital display

Garbage in, garbage out: The hidden data crisis in pharma

This hidden data crisis is the fundamental barrier to scaling AI in the life sciences sector.

Digital

e-clinical trials concept

How integrated patient experience platforms are revolutionis...

AI-powered integrated platforms offer an elemental shift in the way that clinical trials are conducted.

Market Access

Market Access

US and UK flags in the wind

The UK-US drug pricing deal: A welcome step, but not the fin...

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

Market Access

Globe superimposed over Bangkok

Sustaining the mature product portfolio through strategic ou...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

Editor's Picks

UK and US agree zero tariffs on pharma – with price rises

FDA clears trial of 'vectorised' ALS antibody from VectorY

Tracy Beth Hoeg will be fifth CDER head this year

FDA takes steps to limit non-human primate testing

FDA could hike user fees for ex-US drug programmes

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Oncology

Medically accurate representation of a cancer cell

Radiopharmaceutical innovation: Giving cancer drugs second c...

Molecular recycling could transform the economics and innovation of oncology drug discovery.

Oncology

Tumour representation at cellular level

ESMO 2025 in review: A new era in oncology, from AI to next-...

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

Patients

Patients

pharmaphorum podcast Episode 228, Ruth Chambers, Raparu Consult CIC

The NHS, system burden, and a transformation prescription, w...

Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.

Patients

circle of community in wooden figures

How connection can create impact in healthcare: Patient advo...

At ESMO 2025 in Berlin, VML Health presented the inaugural Patient Advocacy Summit.

Patients

A female patient takes a pharmacy delivery directly

DTC pharma is America’s newest care pathway. TrumpRx has exp...

Today’s DTP platforms vary widely in standards, screening protocols, clinical follow-up, data use, and integration with a patient’s broader care team

R&D

R&D

Cells under microscope

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

R&D

immersive medical education

The case for engagement in medical training: Why interactive...

Trainees need to be maximally empowered to connect the dots before they enter hospitals or labs.

R&D

pharmaphorum podcast Episode 227, Punit Dhillon, Skye Bioscience

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

Editor's Picks

UK and US agree zero tariffs on pharma – with price rises

FDA clears trial of 'vectorised' ALS antibody from VectorY

Tracy Beth Hoeg will be fifth CDER head this year

FDA takes steps to limit non-human primate testing

FDA could hike user fees for ex-US drug programmes

News

CHMP decision levels the playing field for GSK's RSV jab

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company